Jovan K. Popović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jovan K. Popović has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Milan R. Rapaic
Computer and Control Department, Faculty of Technical Sciences, University of Novi Sad, 21000 Novi Sad, Serbia
6 shared publications - Stevan Pilipović
Department of Mathematics and Informatics, Faculty of Sciences, University of Novi Sad, Novi Sad, Serbia
6 shared publications Teodor M. Atanacković
Faculty of Technical Sciences, Institute of Mechanics, University of Novi Sad, 21000 Novi Sad, Serbia
6 shared publications- Ana Pilipović
Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia
4 shared publications Milica T. Atanacković
Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Republic of Serbia
4 shared publicationsA. Sabo
1 shared publication
Latest Publications
- 23 January 2013
- Published by Elsevier in Communications in Nonlinear Science and Numerical Simulation
- Vol. 18 (9) , 2507-2514
Two compartmental fractional derivative model with fractional derivatives of different order
- 23 January 2013
- Published by Elsevier in Communications in Nonlinear Science and Numerical Simulation
- Vol. 18 (9) , 2507-2514
Two compartmental fractional derivative model with fractional derivatives of different order
- 24 April 2012
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 37 (4) , 301-307
Effect of fullerenol C60(OH)24 on lipid peroxidation of kidneys, testes and lungs in rats treated with doxorubicine
The aim of this study is to investigate the protective effect of fullerenol C60(OH)24 in various doses, on lipid peroxidation of rat’s kidneys, testes and lungs after application of doxorubicin. The experiment was performed on healthy male Wistar rats. The animals were randomly divided into five experimental groups and treated with saline (0.9 % NaCl i.v.), doxorubicin alone (10 mg/kg i.v.), combination of doxorubicin/fullerenol (50 and 100 mg/kg fullerenol, respectively, 30 min before the introduction of doxorubicin) and fullerenol alone (100 mg/kg), respectively. Animals were killed on the 2nd and 14th day after treatment. Products of lipid peroxidation and thiobarbituric acid are determined spectrophotometrically from the crude homogenate fraction of the kidney, testis and lung tissues of the rats. Fullerenol, applied as a pre-treatment of doxorubicin, significantly reduced or completely prevented the appearance of doxorubicin toxicity in kidneys and testes, in both tested doses. A dose of 100 mg/kg i.p. exhibited a better protective effect. When fullerenol was applied alone, at a dose of 100 mg/kg i.p, it did not significantly affect the intensity of lipid peroxidation in all tested organs.
- 24 April 2012
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 37 (4) , 301-307
Effect of fullerenol C60(OH)24 on lipid peroxidation of kidneys, testes and lungs in rats treated with doxorubicine
The aim of this study is to investigate the protective effect of fullerenol C60(OH)24 in various doses, on lipid peroxidation of rat’s kidneys, testes and lungs after application of doxorubicin. The experiment was performed on healthy male Wistar rats. The animals were randomly divided into five experimental groups and treated with saline (0.9 % NaCl i.v.), doxorubicin alone (10 mg/kg i.v.), combination of doxorubicin/fullerenol (50 and 100 mg/kg fullerenol, respectively, 30 min before the introduction of doxorubicin) and fullerenol alone (100 mg/kg), respectively. Animals were killed on the 2nd and 14th day after treatment. Products of lipid peroxidation and thiobarbituric acid are determined spectrophotometrically from the crude homogenate fraction of the kidney, testis and lung tissues of the rats. Fullerenol, applied as a pre-treatment of doxorubicin, significantly reduced or completely prevented the appearance of doxorubicin toxicity in kidneys and testes, in both tested doses. A dose of 100 mg/kg i.p. exhibited a better protective effect. When fullerenol was applied alone, at a dose of 100 mg/kg i.p, it did not significantly affect the intensity of lipid peroxidation in all tested organs.
- 30 July 2011
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 36 (4) , 189-196
A nonlinear two compartmental fractional derivative model
This study presents a new nonlinear two compartmental model and its application to the evaluation of valproic acid (VPA) pharmacokinetics in human volunteers after oral administration. We have used literature VPA concentrations. In the model, the integer order derivatives are replaced by derivatives of real order often called fractional order derivatives. Physically that means that the history (memory) of a biological process, realized as a transfer from one compartment to another, is taken into account with the mass balance conservation observed. Our contribution is the analysis of a specific nonlinear two compartmental model with the application in evaluation of VPA pharmacokinetics. The agreement of the values predicted by the proposed model with the values obtained through experiments is shown to be good. Thus, pharmacokinetics of VPA after oral application can be described well by a nonlinear two compartmental model with fractional derivatives of the same order proposed here. Parameters in the model are determined by the least-squares method and the particle swarm optimization (PSO) numerical procedure is used. The results show that the nonlinear fractional order two compartmental model for VPA pharmacokinetics is superior in comparison to the classical (integer order) linear two compartmental model and to the linear fractional order two compartmental model.
- 30 July 2011
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 36 (4) , 189-196
A nonlinear two compartmental fractional derivative model
This study presents a new nonlinear two compartmental model and its application to the evaluation of valproic acid (VPA) pharmacokinetics in human volunteers after oral administration. We have used literature VPA concentrations. In the model, the integer order derivatives are replaced by derivatives of real order often called fractional order derivatives. Physically that means that the history (memory) of a biological process, realized as a transfer from one compartment to another, is taken into account with the mass balance conservation observed. Our contribution is the analysis of a specific nonlinear two compartmental model with the application in evaluation of VPA pharmacokinetics. The agreement of the values predicted by the proposed model with the values obtained through experiments is shown to be good. Thus, pharmacokinetics of VPA after oral application can be described well by a nonlinear two compartmental model with fractional derivatives of the same order proposed here. Parameters in the model are determined by the least-squares method and the particle swarm optimization (PSO) numerical procedure is used. The results show that the nonlinear fractional order two compartmental model for VPA pharmacokinetics is superior in comparison to the classical (integer order) linear two compartmental model and to the linear fractional order two compartmental model.
- 8 May 2011
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 36 (3) , 183-188
One-compartmental biometric blood loss calculation after cesarean section
Blood loss during cesarean section was calculated based on post-operative decrement of hemoglobin (Hb) and hematocrit (Hct) level. The model used for pregnant women was previously validated for non-pregnant women who underwent gynecological surgery. 1,068 pregnant women who underwent cesarean section and 517 women who underwent gynecological surgery were included in the study. Regression lines between collected (x) and calculated (y) blood loss in pregnant women (y = 0.164 + 0.602x) and non-pregnant (y = 0.255 + 0.750x) women were statistically parallel. This study confirmed the applicability of one-compartmental model based on the drop in Hb levels for blood loss calculations for both gynecological surgery and cesarean section. Improved methods for calculating blood loss, V after cesarean section as V = [0.0115 × body weight (kg) × ln (preoperative Hb/postoperative Hb)] + [0.1905 × height3 (m) × ln (preoperative Hb/postoperative Hb)] + 0.3158 and after gynecological surgery V = [0.004 × body weight (kg) × ln (preoperative Hb/postoperative Hb)] + [0.4624 × height3 (m) × ln (preoperative Hb/postoperative Hb)] + 0.0472 were suggested.
- 8 May 2011
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 36 (3) , 183-188
One-compartmental biometric blood loss calculation after cesarean section
Blood loss during cesarean section was calculated based on post-operative decrement of hemoglobin (Hb) and hematocrit (Hct) level. The model used for pregnant women was previously validated for non-pregnant women who underwent gynecological surgery. 1,068 pregnant women who underwent cesarean section and 517 women who underwent gynecological surgery were included in the study. Regression lines between collected (x) and calculated (y) blood loss in pregnant women (y = 0.164 + 0.602x) and non-pregnant (y = 0.255 + 0.750x) women were statistically parallel. This study confirmed the applicability of one-compartmental model based on the drop in Hb levels for blood loss calculations for both gynecological surgery and cesarean section. Improved methods for calculating blood loss, V after cesarean section as V = [0.0115 × body weight (kg) × ln (preoperative Hb/postoperative Hb)] + [0.1905 × height3 (m) × ln (preoperative Hb/postoperative Hb)] + 0.3158 and after gynecological surgery V = [0.004 × body weight (kg) × ln (preoperative Hb/postoperative Hb)] + [0.4624 × height3 (m) × ln (preoperative Hb/postoperative Hb)] + 0.0472 were suggested.
- 23 December 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 38 (1) , 163-164
Erratum to: A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac
- 23 December 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 38 (1) , 163-164
Erratum to: A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac
- 10 April 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 37 (2) , 217-220
Remarks on the mass balance for multi-compartmental models; a nonlinear compartmental model
- 10 April 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 37 (2) , 217-220
Remarks on the mass balance for multi-compartmental models; a nonlinear compartmental model
- 18 February 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 37 (2) , 135-136
Erratum to: A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac
- 18 February 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 37 (2) , 135-136
Erratum to: A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac
- 14 January 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 37 (2) , 119-134
A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac
This study presents a new two compartmental model and its application to the evaluation of diclofenac pharmacokinetics in a small number of healthy adults, during a bioequivalence trial. In the model the integer order derivatives are replaced by derivatives of real order often called fractional order derivatives. Physically that means that a history (memory) of a biological process, realized as a transfer from one compartment to another one with the mass balance conservation, is taken into account. This kind of investigations in pharmacokinetics is founded by Dokoumetzidis and Macheras through the one compartmental models while our contribution is the analysis of multi-dimensional compartmental models with the applications of the two compartmental model in evaluation of diclofenac pharmacokinetics. Two experiments were preformed with 12 healthy volunteers with two slow release 100 mg diclofenac tablet formulations. The agreement of the values predicted by the proposed model with the values obtained through experiments is shown to be good. Thus, pharmacokinetics of slow release diclofenac can be described well by a specific two compartmental model with fractional derivatives of the same order. Parameters in the model are determined by the least-squares method and the Particle Swarm Optimization (PSO) numerical procedure is used. The results show that the fractional order two compartmental model for diclofenac is superior in comparison to the classical two compartmental model. Actually this is true in general case since the classical one is a special case of the fractional one.
- 14 January 2010
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 37 (2) , 119-134
A new approach to the compartmental analysis in pharmacokinetics: fractional time evolution of diclofenac
This study presents a new two compartmental model and its application to the evaluation of diclofenac pharmacokinetics in a small number of healthy adults, during a bioequivalence trial. In the model the integer order derivatives are replaced by derivatives of real order often called fractional order derivatives. Physically that means that a history (memory) of a biological process, realized as a transfer from one compartment to another one with the mass balance conservation, is taken into account. This kind of investigations in pharmacokinetics is founded by Dokoumetzidis and Macheras through the one compartmental models while our contribution is the analysis of multi-dimensional compartmental models with the applications of the two compartmental model in evaluation of diclofenac pharmacokinetics. Two experiments were preformed with 12 healthy volunteers with two slow release 100 mg diclofenac tablet formulations. The agreement of the values predicted by the proposed model with the values obtained through experiments is shown to be good. Thus, pharmacokinetics of slow release diclofenac can be described well by a specific two compartmental model with fractional derivatives of the same order. Parameters in the model are determined by the least-squares method and the Particle Swarm Optimization (PSO) numerical procedure is used. The results show that the fractional order two compartmental model for diclofenac is superior in comparison to the classical two compartmental model. Actually this is true in general case since the classical one is a special case of the fractional one.
- 1 June 2009
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 34 (2) , 85-91
Evaluation of statistical power function for various diclofenac bioequivalence trials with different subject numbers
This study presents application of statistical power function for thet-test and ANOVAF-test on the evaluation of diclofenac bioequivalence in trials with the wide variations in sample sizes (N=12, 18 and 24). The power function, together with appropriate equations tables and figures, is used to calculate the power of the ANOVA for crossover design, the number of subjects for a given value of power and the minimum detectable difference in treatment means for different pharmacokinetic parameters of the formulations. The power of the trial with a small, sample size (N=12) to detect 20% differences between diclofenac formulations is shown to be more than 0.9 and almost the same as the power of the trial with a large sample size (N=24). In all trials for all pharmacokinetic parameters the power to detect 20% difference is shown to be more than 0.8. For the power of 0.8, the needed subject number to detect 20% difference in treatment means is the same or smaller than used and the minimum detectable difference is smaller than 20% in all our trials. This investigation shows that bioequivalence studies with small number of subjects (N=12) may be quite adequate for valid conclusions.
- 1 June 2009
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 34 (2) , 85-91
Evaluation of statistical power function for various diclofenac bioequivalence trials with different subject numbers
This study presents application of statistical power function for thet-test and ANOVAF-test on the evaluation of diclofenac bioequivalence in trials with the wide variations in sample sizes (N=12, 18 and 24). The power function, together with appropriate equations tables and figures, is used to calculate the power of the ANOVA for crossover design, the number of subjects for a given value of power and the minimum detectable difference in treatment means for different pharmacokinetic parameters of the formulations. The power of the trial with a small, sample size (N=12) to detect 20% differences between diclofenac formulations is shown to be more than 0.9 and almost the same as the power of the trial with a large sample size (N=24). In all trials for all pharmacokinetic parameters the power to detect 20% difference is shown to be more than 0.8. For the power of 0.8, the needed subject number to detect 20% difference in treatment means is the same or smaller than used and the minimum detectable difference is smaller than 20% in all our trials. This investigation shows that bioequivalence studies with small number of subjects (N=12) may be quite adequate for valid conclusions.
- 1 December 2007
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 32 (6) , 595-602
Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women
To study the effect of pregnancy on postoperative ceftriaxone, cefazolin and gentamicin elimination rate constant, half-life, volume of distribution and systemic clearance. Fifty-four patients undergoing caesarean section and 12 undergoing gynaecological surgery were given intravenous dose of ceftriaxone, cefazolin or gentamicin immediately before the operation, for chemoprophylaxis. The levels of antibiotics were measured in blood plasma, amniotic fluid and umbilical cord blood plasma by HPLC for the cephalosporins and by fluorescence polarization immunoassay for gentamicin. Pharmacokinetic parameters were estimated using a one-compartment model. Pregnancy significantly influenced the pharmacokinetics of ceftriaxone and gentamicin, but not that of cefazolin. Ceftriaxone constant of elimination decreased statistically significantly in caesarean-sectioned women relative to the non-pregnant subjects. Gentamicin constant of elimination increased significantly in caesarean-sectioned women relative to the controls. The concentrations of antibiotics in umbilical cord blood were higher, whereas they were substantially lower in amniotic fluid than in maternal plasma. Six hours after antibiotic administration, only the cefazolin concentrations exceeded the MIC for sensitive bacteria both in pregnant and in non-pregnant patients. Analysis of the pharmacokinetic data suggests that a single-dose of cefazolin may well be the optimal preoperative prophylactic treatment for obstetrical and gynaecological surgical procedures.
- 1 December 2007
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 32 (6) , 595-602
Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women
To study the effect of pregnancy on postoperative ceftriaxone, cefazolin and gentamicin elimination rate constant, half-life, volume of distribution and systemic clearance. Fifty-four patients undergoing caesarean section and 12 undergoing gynaecological surgery were given intravenous dose of ceftriaxone, cefazolin or gentamicin immediately before the operation, for chemoprophylaxis. The levels of antibiotics were measured in blood plasma, amniotic fluid and umbilical cord blood plasma by HPLC for the cephalosporins and by fluorescence polarization immunoassay for gentamicin. Pharmacokinetic parameters were estimated using a one-compartment model. Pregnancy significantly influenced the pharmacokinetics of ceftriaxone and gentamicin, but not that of cefazolin. Ceftriaxone constant of elimination decreased statistically significantly in caesarean-sectioned women relative to the non-pregnant subjects. Gentamicin constant of elimination increased significantly in caesarean-sectioned women relative to the controls. The concentrations of antibiotics in umbilical cord blood were higher, whereas they were substantially lower in amniotic fluid than in maternal plasma. Six hours after antibiotic administration, only the cefazolin concentrations exceeded the MIC for sensitive bacteria both in pregnant and in non-pregnant patients. Analysis of the pharmacokinetic data suggests that a single-dose of cefazolin may well be the optimal preoperative prophylactic treatment for obstetrical and gynaecological surgical procedures.